Horizon Pharma (HZNP) Misses Q1 EPS by 2c, Lowers Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. FND
9. DASH
10. GILD

Go back to Horizon Pharma (HZNP) Misses Q1 EPS by 2c, Lowers Outlook

Horizon Pharma plc Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance

May 8, 2017 7:00 AM EDT

-- First-Quarter 2017 Net Sales of $220.9 Million; Up 8 Percent --

-- First-Quarter 2017 Net Loss of $90.6 Million; Adjusted EBITDA of $51.9 Million --

-- First-Quarter 2017 Net Sales from Rare Disease Medicines Increased 75 Percent and Represented 65 Percent of Total Company Net Sales --

-- Increased Investment in its Rapidly Growing Orphan Biologic Medicine for Refractory Chronic Gout, KRYSTEXXA® --

-- Raising KRYSTEXXA Peak Annual Net Sales Estimate to More than $400 Million from More than $250 Million ---- Announces Acquisition of River Vision... More